Roland E. Schmieder

Featured in: Favicon

nature.com Favicon

jamanetwork.com Favicon

medscape.com Favicon

thelancet.com Favicon

internationaljournalofcardiology.com Favicon

radcliffecardiology.com Favicon

onlinelibrary.wiley.com

Articles

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial | Nature Medicine

Jun 24, 2024 | nature.com | Peter Rossing |David M. Charytan |José Luis Gorriz |Linong Ji |Roland E. Schmieder

AbstractPeople with type-2-diabetes (T2D) and chronic kidney disease (CKD), have a high risk for kidney failure and cardiovascular (CV) complications. Glucagon-like-peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose co-transporter-2 inhibitors (SGLT2i) independently reduce cardiovascular and kidney events. The effect of combining both is unclear.
Renal Denervation in Patients With Chronic Kidney Disease

May 30, 2023 | medscape.com | Roland E. Schmieder

closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →